Washington State Vaccine Program: Current Vaccines and Thimerosal Content

Vaccine	Trade Name/Manufacturer	Thimerosal Content
DT ^[1]	DT (Sanofi-Pasteur)	Trace <.0012% thimerosal
DTaP	Infanrix (GlaxoSmithKline)	None
Haemophilus Influenzae type b	ActHIB (Sanofi-Pasteur)	None
Hepatitis A	Havrix (GlaxoSmithKline)	None
Hepatitis B	Recombivax (Merck)	None
Inactivated Poliovirus	IPOL (Sanofi-Pasteur)	None
Influenza (multi-dose vial) ^[2]	Fluzone (Sanofi-Pasteur)	25 μg/0.5 mL dose
Influenza (single-dose prefilled)	Fluviron (Chiron)	1.0 μg/5 mL dose
Influenza PF (pediatric formula) for children <3 years of age	Fluzone PF (Sanofi-Pasteur)	None
Meningococcal	Menactra (Sanofi-Pasteur)	None
MMR	MMRII (Merck)	None
Pneumococcal conjugate	Prevnar (Wyeth Lederle)	None
Pneumococcal Polysaccharide ^[3]	Pneumovax 23 (Merck)	None
Td	Decavac (Sanofi-Pasteur)	None
Tdap		None
Varicella	Varivax (Merck)	None

^[1] Vaccine is not routinely recommended—DT is used at the physician's discretion for children who cannot tolerate, or whose parents chose to exclude the acellular pertussis component of DTaP.

^[2] Influenza vaccine is not routinely recommended to all children aged 3 years and up. It is not recommended for those with certain medical conditions that put them at increased risk for severe consequences of influenza, or who may expose high risk individuals such as young infants or those with medical conditions that place them at high risk for severe consequences from influenza disease

^[3] Pneumococcal Polysaccharide vaccine is only recommended for children with medical conditions that put them at increased risk for pneumococcal disease.